Bone Biologics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBLG research report →
Price Chart
About the company
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments.
- CEO
- Jeffrey Frelick
- IPO
- 2021
- Employees
- 2
- HQ
- Burlington, MA, US
Get TickerSpark's AI analysis on BBLG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.10M
- P/E
- -0.33
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.28
- EV/EBITDA
- 1.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -57.85%
- ROIC
- -78.01%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,234,942
- Net Income
- $-3,108,991+24.4%
- EPS
- $-2.65+45.1%
- OCF Growth
- +34.8%
- FCF Growth
- +34.8%
- 52W High
- $4.13
- 52W Low
- $0.60
- 50D MA
- $1.14
- 200D MA
- $1.37
- Beta
- 0.53
- RSI (14)
- 23
- Avg Volume
- 332.20K
No earnings-call transcripts are available for BBLG yet.
- Free Float
- 99.1%
- Shares Outstanding
- 1.81M
- Float Shares
- 1.79M
of shares held by institutions
7 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Clear Street LLC | 138 | ▲ 138 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 8, 26 | Walsh Deina H | other | 8,335 |
| Jan 8, 26 | Frelick Jeff | other | 16,668 |
| Jun 4, 25 | Meikle Phillip Terry II | other | 62,894 |
| Jun 4, 25 | Angle Siddhesh Rajendra | other | 62,894 |
| Jun 4, 25 | Stroever Bruce | other | 62,894 |
| Jun 4, 25 | Gagnon Robert E. | other | 62,894 |
| Jan 15, 25 | Frelick Jeff | other | 54,110 |
| Jan 15, 25 | Walsh Deina H | other | 27,055 |
| Oct 16, 24 | Meikle Phillip Terry II | other | 28,185 |
| Oct 16, 24 | Meikle Phillip Terry II | other | 9 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BBLG coverage
Recent articles, reports, and earnings notes.
No research on BBLG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BBLG report →Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
globenewswire.com · Aug 12
Bone Biologics (BBLG) to Announce Earnings on Thursday
defenseworld.net · Aug 6
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
globenewswire.com · Jul 23
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
globenewswire.com · Jul 7
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
globenewswire.com · Jan 8
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
globenewswire.com · Dec 23
Bone Biologics (NASDAQ:BBLG) Shares Down 0.5% – Should You Sell?
defenseworld.net · Dec 11
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
businesswire.com · Sep 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.